Drug profile · INN
abatacept
ORENCIA
abatacept (ORENCIA) is a t-lymphocyte activation antigen cd80 inhibitor. Associated with Bristol-Myers Squibb Australia Pty Ltd. Route of administration: iv (infusion). Current US regulatory status: approved.
Drug details — abatacept
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- IV (INFUSION)
- Patents
- 20
- Programs
- 10
- Data quality
- 0.84
Quick answer
abatacept (ORENCIA) is a t-lymphocyte activation antigen cd80 inhibitor. Associated with Bristol-Myers Squibb Australia Pty Ltd. Route of administration: iv (infusion). Current US regulatory status: approved.
Key facts
Mechanism of action
T-lymphocyte activation antigen CD80 inhibitor
Primary target: T-lymphocyte activation antigen CD80
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12427137
Method for reducing methane production in animal stomach
granted -
US 12389931
Oyster peptide with effect of improving sexual function and preparation method thereof
granted -
US 12324798
Leonurine nanocomposite hydrogel and preparation methods and applications thereof
granted -
US 12297300
Hyaluronic acid-based zwitterionic polymer brush, preparation method thereof, and use thereof
granted -
US 12291530
GLP-1R agonist and therapeutic method thereof
granted -
US 12269808
Amino dithioperacid thioester compound, preparation method therefor, and use thereof
granted -
US 12234236
GLP-1R agonist and therapeutic method thereof
granted -
US 12226476
Helper epitope peptide and application thereof
granted -
US 12221414
Quaternary ammonium salt compound, preparation method therefor and use thereof
granted -
US 12144881
Cosmetic composition containing α-mangostin, method for preparation, and uses thereof
granted -
US 12110315
Fish-derived peptidoglycan recognition protein mutant and application thereof
granted -
US 12090227
Method to improve the encapsulation efficiency and physicochemical stability of ginsenosides Rg3 and CK nano-emulsion
granted -
US 12090156
Application of CB-839 in preparation of drug for inhibiting corneal neovascularization (CNV)
granted -
US 12048317
Astaxanthin-containing condiment and a preparation method therefor
granted -
US 12016950
Devices and methods for treating ear pain
granted -
US 11980602
Cannabinoid prodrug compounds
granted -
US 11976098
Cooked millet prolamin peptide for inhibiting alpha-amylase and alpha-glucosidase
granted -
US 11970523
Long-acting oxyntomodulin hybrid peptide, preparation method therefor, and application thereof
granted -
US 11970479
3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor
granted -
US 11963970
Preparation method of ginseng composition with high ginsenoside bioavailability
granted
Frequently asked questions
What is abatacept?
abatacept (ORENCIA) is a t-lymphocyte activation antigen cd80 inhibitor. Associated with Bristol-Myers Squibb Australia Pty Ltd. Route of administration: iv (infusion). Current US regulatory status: approved.
What is the brand name for abatacept?
ORENCIA is a marketed brand name for abatacept. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of abatacept?
abatacept has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.